LONZA SOLUTIONS AG – Trademark Portfolio
Entity Type: 03
LONZA SOLUTIONS AG holds 28 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 15 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 4 Nice Classification classes. Currently, 14 trademarks are registered. Notable registered marks include META, AXCELA, BARDAC, BARLOX, and NIACIN. The owner is based in VISP.
LONZASTRASSE
VISP 3930 , CH
Showing of trademarks Trademarks
Trademark Classifications
LONZA SOLUTIONS AG's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does LONZA SOLUTIONS AG have?
LONZA SOLUTIONS AG has 28 U.S. trademarks filed with the USPTO. Of these, 14 registered, 12 abandoned, 2 cancelled.
What trademark classes does LONZA SOLUTIONS AG file in?
LONZA SOLUTIONS AG files trademarks across 4 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are LONZA SOLUTIONS AG's most well-known trademarks?
LONZA SOLUTIONS AG's registered trademark portfolio includes well-known marks such as META, AXCELA, BARDAC, BARLOX, and NIACIN. These are among 14 currently registered trademarks in the portfolio.
What is LONZA SOLUTIONS AG's trademark registration success rate?
LONZA SOLUTIONS AG has a 50% trademark registration rate, with 14 out of 28 resolved applications resulting in successful registration. Currently, 0 applications are pending review.